Literature DB >> 26885949

Annual Iron Loss Associated with Hemodialysis.

Tatsuo Tsukamoto1, Takayuki Matsubara, Yuka Akashi, Morihiro Kondo, Motoko Yanagita.   

Abstract

BACKGROUND: In order to keep up the optimal iron status in chronic hemodialysis patients, it is important to know how much iron is lost due to hemodialysis. Residual blood associated with the hemodialysis procedure together with blood sampling inevitably causes the loss of iron in chronic hemodialysis patients. Recent advances in hemodialysis techniques might have reduced this complication. In this cross-sectional study, we directly measured total iron loss by hemodialysis.
METHODS: Two hundred thirty-nine patients who received chronic hemodialysis at Otowa Memorial Hospital were enrolled; 65.7% of patients were men, and mean age was 67 ± 6.4 years (mean ± SD) and 43.2% were diabetic. Residual blood in blood tubing set and dialyzer after rinse back with saline was collected and homogenized. The iron content including free, protein-bound and heme iron was measured using an atomic absorption spectrometry.
RESULTS: The mean iron content in residual blood was 1,247.3 ± 796.2 µg (mean ± SD) and the median was 1,002 µg (95% CI 377.6-3,461.6 µg), indicating 160.8 mg (95% CI 58.9-540.0 mg) iron loss annually when hemodialysis was performed 156 times a year. Fifty milliliter whole blood for monthly blood test and another 2 ml of whole blood lost by paracentesis at every dialysis session contains 228.6 and 118.9 mg iron at 11 g/dl hemoglobin, respectively. Therefore, an annual total iron loss due to hemodialysis comes to 508.3 mg (95% CI 406.4-887.5 mg).
CONCLUSIONS: Five hundred milligram of annual iron supplementation might be sufficient to maintain iron status in hemodialysis patients, which is less than the dose recommended as 1,000-2,000 mg a year. Further study will be required to verify this iron supplementation dosage with recent hemodialysis procedure.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26885949     DOI: 10.1159/000444335

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  How Is Body Composition and Nutrition Status Associated with Erythropoietin Response in Hemodialyzed Patients? A Single-Center Prospective Cohort Study.

Authors:  Wiktoria Feret; Krzysztof Safranow; Kazimierz Ciechanowski; Ewa Kwiatkowska
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

2.  Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.

Authors:  Chie Ogawa; Ken Tsuchiya; Naohisa Tomosugi; Fumiyoshi Kanda; Kunimi Maeda; Teiryo Maeda
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

3.  Survival and analysis of predictors of mortality in patients undergoing replacement renal therapy: a 20-year cohort.

Authors:  Emily de Souza Ferreira; Tiago Ricardo Moreira; Rodrigo Gomes da Silva; Glauce Dias da Costa; Luciana Saraiva da Silva; Samantha Bicalho de Oliveira Cavalier; Beatriz Oliveira Silva; Heloísa Helena Dias; Luiza Delazari Borges; Juliana Costa Machado; Rosângela Minardi Mitre Cotta
Journal:  BMC Nephrol       Date:  2020-11-23       Impact factor: 2.388

Review 4.  Challenging patient phenotypes in the management of anaemia of chronic kidney disease.

Authors:  Sheena Pramod; David S Goldfarb
Journal:  Int J Clin Pract       Date:  2021-08-12       Impact factor: 3.149

Review 5.  Intradialytic Nutrition and Hemodialysis Prescriptions: A Personalized Stepwise Approach.

Authors:  Giorgina Barbara Piccoli; Francoise Lippi; Antioco Fois; Lurlynis Gendrot; Louise Nielsen; Jerome Vigreux; Antoine Chatrenet; Claudia D'Alessandro; Gianfranca Cabiddu; Adamasco Cupisti
Journal:  Nutrients       Date:  2020-03-16       Impact factor: 5.717

6.  In Vitro and In Vivo Evaluations of Mesoporous Iron Particles for Iron Bioavailability.

Authors:  Jung-Feng Lin; Chau-Chung Wu; Yu-Jiun Liao; Subhaini Jakfar; Zi-Biao Tang; Jhewn-Kuang Chen; Feng-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

7.  Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.

Authors:  Kai-Uwe Eckardt; Rajiv Agarwal; Youssef Mk Farag; Alan G Jardine; Zeeshan Khawaja; Mark J Koury; Wenli Luo; Kunihiro Matsushita; Peter A McCullough; Patrick Parfrey; Geoffrey Ross; Mark J Sarnak; Dennis Vargo; Wolfgang C Winkelmayer; Glenn M Chertow
Journal:  Nephrol Dial Transplant       Date:  2021-11-09       Impact factor: 5.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.